Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal disease after mitomycin C therapy.

W T Hanna, S Krauss, R F Regester

    Cancer
    |December 15, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Quality of Life After Severe Burn Injury: A Case Report.

    Annals of burns and fire disasters·2024
    Same author

    Delayed and fractional use of enzymatic debridement with nexobrid for extensive burn injury: a case report.

    Annals of burns and fire disasters·2018
    Same author

    Versatile, sensitive liquid chromatography mass spectrometry - Implementation of 10 μm OT columns suitable for small molecules, peptides and proteins.

    Scientific reports·2016
    Same author

    Avian influenza surveillance in Central and West Africa, 2010-2014.

    Epidemiology and infection·2014
    Same author

    Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.

    Cell death & disease·2014
    Same author

    Mechanisms of RNA-induced toxicity in CAG repeat disorders.

    Cell death & disease·2013

    Mitomycin C (MMC) and 5-fluorouracil (5-FU) chemotherapy can cause severe kidney damage in adenocarcinoma patients. Two forms of renal impairment were observed, one acute and fatal, the other chronic and progressive.

    Area of Science:

    • Nephrology
    • Oncology
    • Pathology

    Background:

    • Mitomycin C (MMC) and 5-fluorouracil (5-FU) are chemotherapeutic agents used for gastrointestinal and pancreatic adenocarcinoma.
    • Renal toxicity is a known side effect of some chemotherapies, but specific patterns related to MMC require further elucidation.

    Purpose of the Study:

    • To characterize the clinical and pathological features of renal impairment in patients treated with mitomycin C and 5-fluorouracil.
    • To identify distinct clinical entities of MMC-induced nephrotoxicity.

    Main Methods:

    • Retrospective analysis of 14 patients with adenocarcinoma treated with MMC and 5-FU.
    • Clinical data review, including renal function and hematological parameters.
    • Kidney biopsy examination using light and electron microscopy.

    Related Experiment Videos

    Main Results:

    • Two distinct patterns of renal impairment emerged 6-11 months post-MMC therapy.
    • Acute, rapidly fatal renal failure characterized by microangiopathic hemolytic anemia, thrombocytopenia, and primary vascular disease (intimal hyperplasia, fibrin thrombi).
    • Chronic, slowly progressive renal impairment with similar but less pronounced pathological findings and absence of microangiopathic hemolysis.

    Conclusions:

    • Mitomycin C therapy can induce significant renal impairment in adenocarcinoma patients, presenting as two distinct clinical syndromes.
    • The acute form is associated with severe microangiopathic hemolysis and vascular pathology, while the chronic form progresses more slowly.
    • Understanding these distinct entities is crucial for managing chemotherapy-related nephrotoxicity.